Home › Gestational Diabetes › NCT05917587
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
RecruitingEarly phase 1Healthy volunteers welcome
Who can join
Ages 18 to 45 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * ≥12 weeks and ≤5 years postpartum * history of GDM or healthy pregnancy Exclusion Criteria: * prediabetes or diabetes (HbA1c ≥5.7%) * current tobacco use * cardiovascular or metabolic disease * cardiovascular or metabolic medication * history of hypertension during pregnancy * current pregnancy
About the study
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
What is being tested
- Metformin Hydrochloride (drug)
- placebo (other)
Sponsor: Anna Stanhewicz, PhD · Participants: 30 · Started: Sep 11, 2024
Contact the study team
- Anna Stanhewicz, PhD · Phone: 3194671732
Official record on ClinicalTrials.gov — NCT05917587
Locations in the U.S.
| Iowa | University of Iowa, Iowa City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.